Abstract:Background: Although neuregulin-1 (NRG1) fusions are known to be oncogenic drivers for lung cancer, chemotherapy is the major regimen for patients with advanced non-small-cell lung cancer (NSCLC). The efficacy and survival outcomes of pemetrexed-based treatments in patients with NRG1 fusion-positive NSCLC have not been established.Methods: We enrolled NSCLC patients with NRG1 fusions based on DNA/RNA-based next-generation sequencing (NGS). The study was conducted to determine the efficacy of treatment regimens in NRG1 fusion-positive advanced NSCLC patients. We also compared the survival outcomes among advanced NSCLC patients with different subtypes of NRG1 fusions.Results: A total of 42 advanced NSCLC patients with NRG1 fusions were enrolled. The subtypes of NRG1 fusions included CD74 (24/42 [57.1%]), which was the most common fusion partner, as well as other subtypes. Twenty-six patients were tested for PD-L1 expression, 24 of whom received a pemetrexed-based regimen as first-line treatment. Five patients received afatinib-targeted therapy. Of the patients who received pemetrexed-based chemotherapy, the median progression-free survival (PFS) was longer than patients who were not treated with pemetrexed-based chemotherapy (5.0 months vs. 2.5 months, P = 0.0279). Notably, among patients treated with afatinib, the overall response rate (ORR) was 40% (2/5) and the PFS was 3 months (95% confidence interval [CI], 0.853–5.147). No differences in median overall survival [OS] (21.0 months vs. 17.0 months, P = 0.6528) were observed between the pemetrexed-based chemotherapy and non-pemetrexed-based therapy groups. Significant differences in OS were detected among patients with different NRG1 fusion subtypes (P = 0.0373).Conclusions: Pemetrexed-based treatment could be effective in advanced NSCLC Chinese patients with NRG1 fusions. The development of more effective treatment strategies is worthy of further study for patients harboring NRG1 fusions.Funding Information: This study was granted by National Natural Science Foundation of China (81873277), the Zhejiang Chinese Medical Science and Technology Foundation (2021ZQ013), Xisike-Hanson Cancer Research Foundation (Y-HS2019-20), and Huilan Public-Hanson Pharmaceutical Lung Cancer Precision Medical Research Special Fund Project Foundation (HL-HS2020-5).Declaration of Interests: All authors declare no conflicts of interest.Ethics Approval Statement: Approval of the study protocol was obtained from Nanjing University of Chinese Medicine Institutional Review Board Committee (approval number: 2022NL-KS045). Individual consent for this retrospective analysis was waived.

Analysis on the pathogenesis and treatment progress of NRG1 fusion-positive non-small cell lung cancer

Advances in Diagnosis and Treatment of HER2-positive Non-small Cell Lung Cancer

Bioinformatics Analyses of the Role of Vascular Endothelial Growth Factor in Patients with Non-Small Cell Lung Cancer.

NRG1 Fusions in NSCLC: Being eNRGy Conscious

Clinicopathologic Features and Response to Therapy of NRG1 Fusion-Driven Lung Cancers: The eNRGy1 Global Multicenter Registry.

Expert Consensus on the Diagnosis and Treatment of NRG1/2 Gene Fusion Solid Tumors

Genomic Characterization and Outcome Evaluation of Kinome Fusions in a Large Non-Small Cell Lung Cancer Population.

A Multicenter Study of NRG1 Fusions in Chinese Non-Small Cell Lung Cancer Patients and Response to Afatinib Using Next Generation Sequencing

Efficacy of Pemetrexed-Based Chemotherapy in Advanced NSCLC Chinese Patients with NRG1 Fusions by TNA Sequencing: A Multicenter Study

NTRK Fusion in Non-Small Cell Lung Cancer: Diagnosis, Therapy, and TRK Inhibitor Resistance

[Afatinib Treatment for Advanced Mixed Non-small Cell Lung Cancer with CRISPLD2-NRG1 Fusion: A Case Report and Literature Review]

Research Progress of Positive ALK Fusion Gene Non-Small Cell Lung Cancer

Molecular Characterization and Prognostic Analysis of Non-Small Cell Lung Cancer: A Single Centric Real-World Study.

Clinical characteristics and targeted therapy of different gene fusions in non-small cell lung cancer: a narrative review

Advances in the Treatment of Rare Mutations in Non-Small Cell Lung Cancer

Advancements in NSCLC: From Pathophysiological Insights to Targeted Treatments

Detection of Novel NRG1, EGFR, and MET Fusions in Lung Adenocarcinomas in the Chinese Population.

Recent progress in targeted therapy for non-small cell lung cancer

P1.03-23 the Molecular Landscape and Outcome of Chinese Patients with Non-Small Cell Lung Cancer Harboring NTRK1 Point Mutations: A Retrospective Study

Advancements in NSCLC

Neuregulin1 acts as a suppressor in human lung adenocarcinoma via AKT and ERK1/2 pathway.